

12 June 2024

Advanced Medical Solutions Group plc  
("AMS" or the "Group")

**Results of Annual General Meeting**

**Winsford, UK:** Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that at the Company's Annual General Meeting held today at 11 am at the Offices of Investec Bank plc, 30 Gresham Street, London, EC2V 7QP, all resolutions were duly passed. Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 13 May 2024.

The poll results were as follows.

Resolution	Title	For	For %	Against	Against %	Total Votes	% Issued Capital
1	FINANCIAL STATEMENTS	136,356,167	99.99%	9,361	0.01%	136,365,528	62.69%
2	REMUNERATION REPORT	134,014,363	98.45%	2,107,730	1.55%	136,122,093	62.58%
3	AUDITOR REMUNERATION	133,257,997	97.65%	3,210,036	2.35%	136,468,033	62.74%
4	RE-ELECT L SHANAHAN	129,648,691	95.22%	6,506,705	4.78%	136,155,396	62.60%
5	RE-ELECT G COOK	129,863,105	95.16%	6,601,163	4.84%	136,464,268	62.74%
6	RE-ELECT D LE FORT	130,840,531	95.88%	5,623,737	4.12%	136,464,268	62.74%
7	RE-ELECT C MEREDITH	132,798,078	97.31%	3,666,187	2.69%	136,464,265	62.74%
8	RE-ELECT E JOHNSON	136,218,616	99.82%	245,652	0.18%	136,464,268	62.74%
9	FINAL DIVIDEND	136,505,565	100.00%	516	0.00%	136,506,081	62.76%
10	DEFERRED BONUS PLAN	136,377,375	99.92%	113,837	0.08%	136,491,212	62.75%
11	LONG TERM INCENTIVE PLAN	135,984,889	99.63%	506,310	0.37%	136,491,199	62.75%
12	DEFERRED SHARE BONUS PLAN	136,190,086	99.78%	300,213	0.22%	136,490,299	62.75%
13	ALLOT SHARES*	135,883,826	99.56%	600,189	0.44%	136,484,015	62.75%
14	PRE-EMPTION RIGHTS*	134,775,458	98.75%	1,708,671	1.25%	136,484,129	62.75%
15	PURCHASE SHARES*	108,148,575	99.92%	82,427	0.08%	108,231,002	49.76%

\* Special Resolution

Notes:  
1. Votes "For" and "Against" are expressed as a percentage of votes received.  
2. A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.  
3. Total number of shares in issue at close of business on 7 June = 217,508,089 shares. 62.75% of the voting capital was instructed.

- End -

For further information, please visit [www.admedsol.com](http://www.admedsol.com) or contact:

**Advanced Medical Solutions Group plc**

Chris Meredith, Chief Executive Officer  
Eddie Johnson, Chief Financial Officer  
Michael King, Investor Relations

Tel: +44 (0) 1606 545508

**ICR Consilium**

Mary-Jane Elliott / Lucy Featherstone

Tel: +44 (0) 20 3709 5700  
[AMS@icrhealthcare.com](mailto:AMS@icrhealthcare.com)

**Investec Bank PLC (NOMAD & Broker)**

Gary Clarence / David Anderson

Tel: +44 (0) 20 7597 5970

**HSBC Bank plc (Broker)**

Sam McLennan / Joe Weaving / Stephanie Cornish

Tel: 44 (0) 20 7991 8888

**About Advanced Medical Solutions Group plc** - see [www.admedsol.com](http://www.admedsol.com)

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made six acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, and Syntacoll, a German specialist in collagen-based absorbable surgical implants.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 900 employees. For more information, please see [www.admedsol.com](http://www.admedsol.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGSFWFEELSELM